Pathogenesis of Obstructive Sleep Apnoea/Hypopnoea Syndrome
Lancet 344:653-655, Douglas,N.J.&Polo,O., 1994
Reversal of Amphotericin-B-Related Encephalopathy
Neurol 44:1183-1184, Balmaceda,C.M.,et al, 1994
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
NEJM 330:585-591, Bensimon,G.,et al, 1994
Amyotrophic Lateral Sclerosis Patient Antibodies Label CA2+Channel a1 Subunit
Ann Neurol 35:164-171, 1311994., Fumiharu,K.,et al, 1994
Botulinum Toxin-A Improves the Rigidity of Progressive Supranuclear Palsy
Ann Neurol 35:237-239, Polo,K.B.&Jabbari,B., 1994
The British Isles Survey of Multiple Sclerosis in Twins
Neurol 44:11-15, Mumford,C.J.,et al, 1994
Pathogenesis of Multiple Sclerosis
Lancet 343:271-275, Ffrench-Constant,C., 1994
Headache
JNNP 57:134-143, Pearce,J.M.S., 1994
Movement Disorders Following Lesions of the Thalamus or Subthalamic Region
Mov Disord 9:493-507, Lee,M.S. &Marsden, C.D., 1994
Aspartame Use in Parkinson's Disease
Neurol 43:611-613, Karstaedt,P.J.&Pincus,J.H., 1993
Nigral Dysfunction in Drug-Induced Parkinsonism:An F-dopa PET Study
Neurol 43:552-556, Burn,D.J.&Brooks,D.J., 1993
Gene Therapy for Neurologic Disease
Arch Neurol 50:1252-1268, Suhr,S.T.&Gage,F.H., 1993
Prognostic Significance of the Onset Mode in Parkinsonism
Neurol 43:829-830, Rajput,A.H.,et al, 1993
PET Imaging of the Dopamine Transporter with 11C-WIN 35, 428 Reveals Marked Declines in Mild Parkinson's Disease
Ann Neurol 34:423-431, Frost,J.J.,et al, 1993
Levodopa Improves Spatial Contrast Sensitivity in Parkinson's Disease
Arch Neurol 50:721-724, Hutton,J.T.,et al, 1993
T2 Relaxation Time in Patients with Parkinson's Disease
Neurol 43:697-700, Antonini,A.,et al, 1993
The Spectrum of Levodopa-Related Fluctuations in Parkinson's Disease
Neurol 43:1459-1464, Riley,D.E.&Lang,A.E., 1993
Blood Levodopa Levels and Unified Parkinson's Disease Rating Scale Function:With and Without Exercise
Neurol 43:1040-1042, Goetz,C.G.,et al, 1993
Contrast Agent Overdose Causing Brain Retention of Contrast, Seizures, and Parkinsonism
Neurol 43:836-838, May,E.F.,et al, 1993
Treatment of Parkinson's Disease
NEJM 329:1021-1027, Calne,D.B., 1993
Clinical Features, Pathogenesis, and Computed Tomographic Characteristics of Internal Watershed Infarction
Stroke 24:1925-1932, Bladin,C.F.&Chambers,B.R., 1993
Clinicopath Conf
progressive Supranuclear Palsy, Case 46-1993, NEJM 329:1560-1567993., , 1993
Prolactin-Secreting Macroadenomas in Adolescents, Response to Bromocriptine Therapy
Am J Dis Child 147:1057-1061, Tyson,D.,et al, 1993
Autosomal Dominant Parkinsoniam with Benign Course and Typical Lewy-Body Pathology
Neurol 43:2222-2227, Golbe,L.I.,et al, 1993
Risk Factors for Nursing Home Placement in Advanced Parkinson's Disease
Neurol 43:2227-2229, Goetz,C.G.&Stebbins,G.T., 1993
Fatigue in Parkinson's Disease
Neurol 43:2016-2018, Friedman,J.&Friedman,H., 1993
Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993
Multictr Study of Cabergoline, A Long-Acting Dopamine Receptor Agonist, in PD Fluct Resp to Levodopa/Carbidopa
Neurol 43:1981-1984, Lieberman,A.,et al, 1993
Olfactory Testing Differentiates Between Progressive Supranuclear Palsy & Idiopathic Parkinson's Dis
Neurol 43:962-965, Doty,R.L.,et al, 1993
Defecatory Function in Parkinson's Disease:Response to Apomorphine
Ann Neurol 33:490-493, Edwards,L.L.,et al, 1993
Multiple System Atrophy & Prog Supranuc Palsy, Dimin Striatal D2 Dopamine Receptor Act by SPECT
Arch Neurol 50:513-516, vanRoyen,E.,et al, 1993
Faithful Fashion:Survival Status of the Brain Transplant Cure for Parkinsonism
Neurol 43:644-649, Landau,W.M., 1993
Practice Parameters:Initial Therapy of Parkinson's Disease
Report of the Quality Standards Subcommittee of AAN, Neurol 43:1296-12971993., , 1993
Clinical Experience with Controlled-Release Carbidopa/Levodopa in Parkinson's Disease
Neurol 43:677-681, Pahwa,R.,et al, 1993
Neurosurgical Horizons in Parkinson's Disease
Neurol 43:1-7, Goetz,C.G.,et al, 1993
A Clinicopathologic Study of 100 Cases of Parkinson's Disease
Arch Neurol 50:140-148, Hughes,A.J.,et al, 1993
Increase of Parkinson Disability after Fluoxetine Medication
Neurol 43:211-213, Steur,E.N.H.J., 1993
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 328:176-1831993., , 1993
Dyslexia, Left-Handedness, and Immune Disorders
Arch Neurol 50:411-416, Tennessen,F.E.,et al, 1993
The Capsular Warning Syndrome:Pathogenesis and Clinical Features
Neurol 43:957-962, Donnan,G.A.,et al, 1993
Evolving Toward Effective Therapy for Acute Ischemic Stroke
JAMA 270:360-364, Fisher,M.&Bogousslavsky,J., 1993
Functional Integration of Cortical Grafts Placed in Brain Infarcts of Rats
Ann Neurol 34:362-368, Grabowski,M.,et al, 1993
Transplants for Stroke Patients
Ann Neurol 34:322-323, Sharp,F.R., 1993
Subcortical Dementia
BMJ 307:1-2, Dunne,F.J., 1993
The Prevalence of Metoclopramide-Induced Tardive Dyskinesia and Acute Extrapyramidal Movement Disorders
Arch Int Med 153:1469-1475, Ganzini,L.,et al, 1993
Apolipoprotein E Polymorphism and Alzheimer's Disease
Lancet 342:697-699, 6961993., Poirier,J.,et al, 1993
Thalamic Stimulation & Prox Tremor, A Specific Target in Nucleus Ventrointermedius Thalamik
Arch Neurol 50:498-500, Nguyen,J-P.&Degos,J-D., 1993
Progression After Chronic Manganese Exposure
Neurol 43:1479-1483, Huang,C.C.,et al, 1993
The Spectrum of Immune Resp to C. Jejuni & Glycoconjugates in Guillain-Barre Synd Other Neuroimmunol Disorders
Ann Neurol 34:136-144, 1251993., Enders,U.,et al, 1993
Human Immunodeficiency Virus Type 1 Infection of the Nervous System:Pathogenetic Mechanisms
Ann Neurol 33:429-436, Epstein,L.G.&Gendelman,H.E., 1993